{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:35:01Z","timestamp":1792859701046,"version":"4.5.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic hepatitis B (CHB) is an infectious disease mainly affecting the liver, caused by the hepatitis B virus (HBV). In the treatment of CHB, pegylated interferon \u03b1-2b (PEG-IFN\u03b1-2b) is one of the important therapeutic options. However, there are significant individual differences in patients\u2019 responses to this treatment and only a few patients can achieve hepatitis B surface antigen (HBsAg) seroclearance. Therefore, an effective method to identify patients with a high likelihood of favorable response at an early stage is urgently needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, we analyzed data from CHB patients who received antiviral treatment with PEG-IFN\u03b1-2b and completed 48 weeks of follow-up in the \u201cOASIS\u201d Project. Patients were divided into the seroclearance group and the non-seroclearance group based on whether HBsAg seroclearance was achieved at week 48.Five distinct machine learning feature selection algorithms were used to identify the optimal predictive variables for HBsAg seroclearance. These key variables were then incorporated into 12 machine learning algorithms to build predictive models for HBsAg seroclearance. The best-performing model was selected, and its performance was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 680 subjects were included in this study, comprising 165 in the 48-week seroclearance group and 515 in the 48-week non-seroclearance group. Through five different machine learning feature selection algorithms, 11 variables were identified and used to construct 12 distinct machine learning models. Comparative analysis of these models, based on the Area Under the Receiver Operating Characteristic Curve (AUC) and Decision Curve Analysis (DCA) results from the training set, indicated that the Random Forest model was the optimal model for predicting HBsAg seroclearance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Random Forest model effectively predicted the 48-week HBsAg seroclearance rate using indicators measured at 24 weeks of PEG-IFN\u03b1-2b therapy. This model can provide a reliable reference for optimizing clinical treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcell.2025.1734654","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:21Z","timestamp":1764138921000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["A machine learning-based predictive model for 48-week hepatitis B surface antigen seroclearance in chronic hepatitis B patients treated with pegylated interferon \u03b1-2b: prediction at week 24"],"prefix":"10.3389","volume":"13","author":[{"given":"Nan","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shike","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luocheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhili","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jhep.2006.09.019","article-title":"Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis c virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels","volume":"46","author":"Akuta","year":"2007","journal-title":"J. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41579-023-00984-1","article-title":"Machine learning for microbiologists","volume":"22","author":"Asnicar","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/a:1010933404324","article-title":"Random forests","volume":"45","author":"Breiman","year":"2001","journal-title":"Mach. Learn."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1002\/hep.22760","article-title":"Hepatitis b virus surface antigen levels: a guide to sustained response to peginterferon alfa\u20102a in hbeag\u2010negative chronic hepatitis b","volume":"49","author":"Brunetto","year":"2009","journal-title":"Hepatol. Baltim. Md"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S1473-3099(24)00307-4","article-title":"Who's 2024 global hepatitis report","volume":"24","author":"Burki","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis b e antigen\u2013positive chronic hepatitis b to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"crossref","DOI":"10.1145\/2939672.2939785","article-title":"Xgboost: a scalable tree boosting system","volume-title":"Paper presented at the","author":"Chen","year":"2016"},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40537-023-00874-6","article-title":"Data-driven multinomial random forest: a new random forest variant with strong consistency","volume":"11","author":"Chen","year":"2024","journal-title":"J. Big Data"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1161\/CIRCULATIONAHA.115.001593","article-title":"Machine learning in medicine","volume":"132","author":"Deo","year":"2015","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.5009\/gnl.2014.8.1.113","article-title":"A low serum \u03b3-glutamyltransferase level predicts a sustained virological response in patients with chronic hepatitis c genotype 1","volume":"8","author":"Dogan","year":"2014","journal-title":"Gut Liver"},{"key":"B11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1186\/s12967-023-04205-4","article-title":"Construction and validation of prognostic models in critically ill patients with sepsis-associated acute kidney injury: interpretable machine learning approach","volume":"21","author":"Fan","year":"2023","journal-title":"J. Transl. Med."},{"key":"B12","first-page":"177","article-title":"All models are wrong, but many are useful: learning a variable's importance by studying an entire class of prediction models simultaneously","volume":"20","author":"Fisher","year":"2019","journal-title":"J. Mach. Learn. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J. Stat. Softw."},{"key":"B14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/diagnostics14010118","article-title":"Prediction model for the clearance of hepatitis b surface antigen in patients with chronic hepatitis b before interferon therapy: a prospective case\u2013control study","volume":"14","author":"Geng","year":"2024","journal-title":"Diagnostics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.3760\/cma.j.cn501113-20221204-00607","article-title":"Guidelines for the prevention and treatment of chronic hepatitis b (version 2022)","volume":"30","author":"Hong","year":"2022","journal-title":"Chin. J. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s40200-022-01076-2","article-title":"Predicting diabetic nephropathy in type 2 diabetic patients using machine learning algorithms","volume":"21","author":"Hosseini Sarkhosh","year":"2022","journal-title":"J. Diabetes and Metabolic Disord."},{"key":"B17","doi-asserted-by":"publisher","first-page":"9957","DOI":"10.3748\/wjg.v21.i34.9957","article-title":"Association of serum gamma-glutamyl transferase with treatment outcome in chronic hepatitis b patients","volume":"21","author":"Huang","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s10489-017-0992-2","article-title":"Feature clustering based support vector machine recursive feature elimination for gene selection","volume":"48","author":"Huang","year":"2018","journal-title":"Appl. Intell."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1093\/nar\/gkv229","article-title":"Robust meta-analysis of gene expression using the elastic net","volume":"43","author":"Hughey","year":"2015","journal-title":"Nucleic. Acids. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"101193","DOI":"10.1016\/j.lanwpc.2024.101193","article-title":"New progress in hbv control and the Cascade of health care for people living with hbv in China: evidence from the fourth national serological survey, 2020","volume":"51","author":"Hui","year":"2024","journal-title":"Lancet Reg. Health-W. Pac."},{"key":"B21","doi-asserted-by":"publisher","first-page":"221","DOI":"10.12449\/JCH250205","article-title":"Research advances in the disease burden of viral hepatitis in China","volume":"41","author":"Jian","year":"2025","journal-title":"J. Clin. Hepatol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.1186\/1471-2105-10-S1-S65","article-title":"A random forest approach to the detection of epistatic interactions in case-control studies","volume":"10","author":"Jiang","year":"2009","journal-title":"BMC Bioinforma."},{"key":"B23","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12072-024-10648-8","article-title":"Predictors of hbsag seroclearance in patients with chronic hbv infection treated with pegylated interferon-\u03b1: a systematic review and meta-analysis","volume":"18","author":"Jiang","year":"2024","journal-title":"Hepatol. Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12859-019-3110-0","article-title":"Random forest-based imputation outperforms other methods for imputing lc-ms metabolomics data: a comparative study","volume":"20","author":"Kokla","year":"2019","journal-title":"BMC Bioinforma."},{"key":"B25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s10462-007-9052-3","article-title":"Machine learning: a review of classification and combining techniques","volume":"26","author":"Kotsiantis","year":"2006","journal-title":"Artif. Intell. Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/liv.15597","article-title":"A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis b","volume":"43","author":"Lee","year":"2023","journal-title":"Liver Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"101391","DOI":"10.1016\/j.jhepr.2025.101391","article-title":"Prediction of long-term hbsag seroclearance in patients with hbeag-negative chronic hepatitis b","volume":"7","author":"Lee","year":"2025","journal-title":"JHEP Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"100384","DOI":"10.1016\/j.advnut.2025.100384","article-title":"Perspective: global burden of iodine deficiency: insights and projections to 2050 using xgboost and shap","volume":"16","author":"Liang","year":"2025","journal-title":"Adv. Nutr."},{"key":"B29","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-pacific consensus statement on the management of chronic hepatitis b: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"105584","DOI":"10.1016\/j.antiviral.2023.105584","article-title":"Mir-548c-3p targets trim22 to attenuate the peg\u2013ifn\u2013\u03b1 therapeutic efficacy in hbeag-positive patients with chronic hepatitis b","volume":"213","author":"Lin","year":"2023","journal-title":"Antivir. Res."},{"key":"B31","article-title":"A unified approach to interpreting model predictions","volume":"30","author":"Lundberg","year":"2017","journal-title":"Adv. Neural Information Processing Systems"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e28963","DOI":"10.1002\/jmv.28963","article-title":"Cxcl13 variant predicts pegylated\u2010interferon \u03b1 treatment response in hbeag\u2010positive chronic hepatitis b patients","volume":"95","author":"Luo","year":"2023","journal-title":"J. Med. Virol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","article-title":"Kinetics of hepatitis b surface antigen differ between treatment with peginterferon and entecavir","volume":"54","author":"Reijnders","year":"2011","journal-title":"J. Hepatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"105163","DOI":"10.1016\/j.antiviral.2021.105163","article-title":"A simple-to-use tool for predicting response to peginterferon in hbv dna suppressed chronic hepatitis b patients in China","volume":"194","author":"Ren","year":"2021","journal-title":"Antivir. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/hep.23722","article-title":"Early on\u2010treatment prediction of response to peginterferon alfa\u20102a for hbeag\u2010negative chronic hepatitis b using hbsag and hbv dna levels","volume":"52","author":"Rijckborst","year":"2010","journal-title":"Hepatology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1093\/cid\/cit121","article-title":"Hla-dp and il28b polymorphisms: influence of host genome on hepatitis b surface antigen seroclearance in chronic hepatitis b","volume":"56","author":"Seto","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1615950","DOI":"10.3389\/fmed.2025.1615950","article-title":"Shap combined with machine learning to predict mortality risk in maintenance hemodialysis patients: a retrospective study","volume":"12","author":"Shu","year":"2025","journal-title":"Front. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"91","DOI":"10.11622\/smedj.2021054","article-title":"Machine learning in medicine: what clinicians should know","volume":"64","author":"Sim","year":"2023","journal-title":"Singap. Med. J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v039.i05","article-title":"Regularization paths for cox's proportional hazards model via coordinate descent","volume":"39","author":"Simon","year":"2011","journal-title":"J. Stat. Softw."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/hep.23844","article-title":"Prediction of sustained response to peginterferon alfa-2b for hepatitis b e antigen\u2013positive chronic hepatitis b using on-treatment hepatitis b surface antigen decline","volume":"52","author":"Sonneveld","year":"2010","journal-title":"Hepatology"},{"key":"B41","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s12072-024-10764-5","article-title":"Predictive model for hbsag clearance rate in chronic hepatitis b patients treated with pegylated interferon \u03b1-2b for 48 weeks","volume":"19","author":"Tan","year":"2025","journal-title":"Hepatol. Int."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1332232","DOI":"10.3389\/fcimb.2023.1332232","article-title":"Clinical cure induced by pegylated interferon \u03b1-2b in the advantaged population of chronic hepatitis b virus infection: a retrospective cohort study","volume":"13","author":"Wen","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1656367","DOI":"10.3389\/fcell.2025.1656367","article-title":"Machine learning based immune evasion signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma","volume":"13","author":"Xue","year":"2025","journal-title":"Front. Cell. Dev. Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12985-024-02599-1","article-title":"A predictive model for functional cure in chronic hbv patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data","volume":"21","author":"Ye","year":"2024","journal-title":"Virol. J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/S2468-1253(24)00237-1","article-title":"Vir-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis b virus infection: a phase 2 study","volume":"9","author":"Yuen","year":"2024","journal-title":"Lancet Gastroenterology and Hepatology"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1734654\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:35:24Z","timestamp":1764138924000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2025.1734654\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":45,"alternative-id":["10.3389\/fcell.2025.1734654"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2025.1734654","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1734654"}}